Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis

World Journal of Gastroenterology

Volumn 20, Issue 2, 2014, Pages 569-577

  Du, Juan ^a   Ma, Yan Yan ^a   Yu, Chao Hui ^a   Li, You Ming ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Meta analysis; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Pentoxifylline

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; INTERLEUKIN 6; PENTOXIFYLLINE; PLACEBO; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID; BIOLOGICAL MARKER;

ARTICLE; HEPATITIS; HUMAN; LIVER FIBROSIS; META ANALYSIS; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEATOSIS; SYSTEMATIC REVIEW (TOPIC); WEIGHT REDUCTION; BLOOD; DRUG EFFECTS; LIVER; LIVER FUNCTION TEST; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; HUMANS; LIVER; LIVER FUNCTION TESTS; NON-ALCOHOLIC FATTY LIVER DISEASE; PENTOXIFYLLINE; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84892838265     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i2.569     Document Type: Article

References (41)

1. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11: 1-16, vii [PMID: 17544968 DOI: 10.1016/j.cld.2007.02.009]
2. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005; 22: 1129-1133 [PMID: 16108837 DOI: 10.1111/j.1464-5491.2005.01748.x]
3. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-894 [PMID: 11567710 DOI: 10.1016/ S0140-6736(01)06042-1]
4. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-544 [PMID: 14987322 DOI: 10.1111/j.1365-2036.2004.01888.x]
5. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188-196 [PMID: 14752837 DOI: 10.1002/ hep.20012]
6. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384 [PMID: 10453959 DOI: 10.1016/S0168-8278(99)80243-8]
7. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004; 174: 193-196 [PMID: 15135271 DOI: 10.1016/j.atherosclerosis.2004.01.008]
8. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48: 119-128 [PMID: 18537181 DOI: 10.1002/ hep.22336]
9. Pamuk GE, Sonsuz A. N-acetylcysteine in the treatment of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2003; 18: 1220-1221 [PMID: 12974918 DOI: 10.1046/ j.1440-1746.2003.03156.x]
10. Després JP, Ross R, Boka G, Alméras N, Lemieux I. Effect of rimonabant on the high-triglyceride/ low-HDLcholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009; 29: 416-423 [PMID: 19112166 DOI: 10.1161/ATVBAHA. 108.176362]
11. Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, Avitabile T, Li Volti G, Galvano F. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial. Am J Gastroenterol 2010; 105: 1338-1345 [PMID: 20068559 DOI: 10.1038/ajg.2009.719]
12. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011; 52: 740-743 [PMID: 21505361 DOI: 10.1097/MPG.0b013e31821f9b85]
13. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, Galvano F. Bifidobacterium longum with fructooligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57: 545-553 [PMID: 21901256 DOI: 10.1007/s10620-011-1887-4]
14. Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 2013; 12: 256-262 [PMID: 23396737]
15. Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol 1994; 30: 603-621 [PMID: 8157787 DOI: 10.1016/ S0190-9622(94)70069-9]
16. Bevan EG, Waller PC, Ramsay LE. Pharmacological approaches to the treatment of intermittent claudication. Drugs Aging 1992; 2: 125-136 [PMID: 1596595 DOI: 10.2165/0000251 2-199202020-00006]
17. Hepgül G, Tanrikulu S, Unalp HR, Akguner T, Erbil Y, Olgaç V, Ademoǧlu E. Preventive effect of pentoxifylline on acute radiation damage via antioxidant and anti-inflammatory pathways. Dig Dis Sci 2010; 55: 617-625 [PMID: 19294507 DOI: 10.1007/s10620-009-0780-x]
18. LeMay LG, Vander AJ, Kluger MJ. The effects of pentoxifylline on lipopolysaccharide (LPS) fever, plasma interleukin 6 (IL 6), and tumor necrosis factor (TNF) in the rat. Cytokine 1990; 2: 300-306 [PMID: 2104230 DOI: 10.1016/1043-4666(90) 90032-O]
19. Zabel P, Schönharting MM, Schade UF, Schlaak M. Effects of pentoxifylline in endotoxinemia in human volunteers. Prog Clin Biol Res 1991; 367: 207-213 [PMID: 1924429]
20. Duman DG, Ozdemir F, Birben E, Keskin O, Ekşioǧlu-Demiralp E, Celikel C, Kalayci O, Kalayci C. Effects of pentoxifylline on TNF-alpha production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2007; 52: 2520-2524 [PMID: 17436095 DOI: 10.1007/s10620-006-9723-y]
21. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-1476 [PMID: 11078773 DOI: 10.1056/NEJM200011163432007]
22. Farrell GC. Is bacterial ash the flash that ignites NASH? Gut 2001; 48: 148-149 [PMID: 11156629 DOI: 10.1136/gut.48.2.206]
23. Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, Cheng CL, Wee A, Lim SG. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008; 2: 196-201 [PMID: 19669304 DOI: 10.1007/s12072-008-9058-1]
24. Tuncer İ, Uygan İ, Dülger H, Türkdoǧan K, Şekeroǧlu MR, Kösem M. The comparative effects of pentoxifylline and ursodeoxycholic acid on IL-1 β, Il-6, Il-8 and TNF-α levels in nonalcoholic fatty liver. E J Med 2003; 8: 27-32
25. Georgescu EF, Georgescu M. Therapeutic options in nonalcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007; 16: 39-46 [PMID: 17410287]
26. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011; 54: 1610-1619 [PMID: 21748765 DOI: 10.1002/hep.24544]
27. Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, Rinella ME. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011; 10: 277-286 [PMID: 21677329]
28. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000 [PMID: 16250043 DOI: 10.1002/ hep.20920]
29. Rodríguez-Hernández H, Cervantes-Huerta M, Rodríguez-Moran M, Guerrero-Romero F. Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet. Ann Hepatol 2011; 10: 486-492 [PMID: 21911890]
30. Clark JM. Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 2006; 40 Suppl 1: S39-S43 [PMID: 16540766]
31. Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009; 48: 587-596 [PMID: 19412008 DOI: 10.1097/MPG.0b013e31818e04d1]
32. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis 2011; 10: 49 [PMID: 21477300 DOI: 10.1186/1476-511X-10-49]
33. Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quiñones L, Varela N, Contreras J, Lazarte R, Csendes A, Rojas J, Maluenda F, Burdiles P, Diaz JC, Smok G, Thielemann L, Poniachik J. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond) 2004; 106: 261-268 [PMID: 14556645 DOI: 10.1042/ CS20030285]
34. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278 [PMID: 7926300 DOI: 10.2337/diabetes. 43.11.1271]
35. Warne JP. Tumour necrosis factor alpha: a key regulator of adipose tissue mass. J Endocrinol 2003; 177: 351-355 [PMID: 12773114 DOI: 10.1677/joe.0.1770351]
36. Crespo J, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez-Díez A, Fernández-Escalante JC, Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-1163 [PMID: 11732005 DOI: 10.1053/jhep.2001.29628]
37. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-820 [PMID: 21319198 DOI: 10.1002/hep.24127]
38. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-1467 [PMID: 8675165 DOI: 10.1002/hep.510230624]
39. Obinata K, Maruyama T, Hayashi M, Watanabe T, Nittono H. Effect of taurine on the fatty liver of children with simple obesity. Adv Exp Med Biol 1996; 403: 607-613 [PMID: 8915401 DOI: 10.1007/978-1-4899-0182-8_67]
40. Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000; 136: 739-743 [PMID: 10839869]
41. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-778 [PMID: 14999696 DOI: 10.1002/hep.20092]